Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 11/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31305414 | 0.89 | DRD2 (0.50) | DRD2SIGMAR1CACNA1HTDP1 | |
| SCHEMBL14873885 | 0.87 | DRD2 (0.55) | MEN1KMT2ADRD2SIGMAR1CACNA1H | |
| SCHEMBL513795 | 0.87 | MEN1 (0.55) | MEN1KMT2ADRD2SIGMAR1CACNA1H | |
| SCHEMBL829612 | 0.86 | DRD2 (0.56) | MEN1KMT2ADRD2SIGMAR1TDP1 | |
| SCHEMBL13021104 | 0.86 | DRD2 (0.46) | DRD2SIGMAR1CACNA1HTDP1 | |
| SCHEMBL31301221 | 0.86 | DRD2 (0.55) | MEN1KMT2ADRD2SIGMAR1CACNA1H | |
| SCHEMBL24913972 | 0.85 | DRD2 (0.57) | MEN1KMT2ADRD2SIGMAR1TDP1 | |
| SCHEMBL22783652 | 0.85 | DRD2 (0.56) | MEN1KMT2ADRD2SIGMAR1CACNA1H | |
| SCHEMBL22783648 | 0.85 | DRD2 (0.52) | MEN1KMT2ADRD2SIGMAR1CACNA1H | |
| SCHEMBL17805291 | 0.84 | DRD2 (0.52) | MEN1KMT2ADRD2SIGMAR1CACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12517130-B2 | Isoindoline derivatives which bind to an ATP binding site | Neophore Limited (GB) | 2026-01-06 | — | — | US | disclosed |
| CN-115397811-B | Isoindoline derivatives binding to ATP binding sites | 奈奥芬莱有限公司 | 2025-05-23 | — | — | CN | disclosed |
| US-20230061002-A1 | ISOINDOLINE DERIVATIVES WHICH BIND TO AN ATP BINDING SITE | Neophore Limited (GB) | 2023-03-02 | — | — | US | disclosed |
| EP-4093731-A1 | ISOINDOLINE DERIVATIVES WHICH BIND TO AN ATP BINDING SITE | Neophore Limited (GB) | 2022-11-30 | — | — | EP | disclosed |
| CN-115397811-A | Isoindoline derivatives that bind to ATP binding sites | 奈奥芬莱有限公司 | 2022-11-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230061002-A1 | ISOINDOLINE DERIVATIVES WHICH BIND TO AN ATP BINDING SITE | MSH2, PMS2, MSH6 | MEN1 744/4885KMT2A 2768/4885DRD2 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.